Exenatide Placebo

DRUG3 trials

Sponsors

Amsterdam UMC, location VUmc, Camillo Ricordi and Jay Skyler, University of Minnesota

Conditions

Autoimmune DiseasesDiabetes MellitusDiabetes Mellitus, Type 1Hyperinsulinemic HypoglycemiaHypoglycemiaType 2 Diabetes

Phase 1

Diabetes Islet Preservation Immune Treatment

WithdrawnNCT02586831

Camillo Ricordi and Jay SkylerAutoimmune Diseases, Diabetes Mellitus, Diabetes Mellitus, Type 1 +1

Start: 2024-06-01End: 2024-06-01Updated: 2026-01-15

Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia

CompletedNCT02685852

University of MinnesotaHyperinsulinemic Hypoglycemia

Start: 2016-02-29End: 2019-07-22Updated: 2021-05-06

Phase 4

SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

CompletedNCT01744236

Amsterdam UMC, location VUmcType 2 Diabetes

Start: 2013-04-30End: 2015-08-31Updated: 2015-12-09

Related Papers

Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes

Diabetes & Metabolism2021-01-1259 citations

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.

2016-09-15114 citations

Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.

2016-08-3046 citations

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

Diabetologia2016-04-01124 citations

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes

BMJ Open2015-11-0130 citations